From: Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China
First author | Publication year | Sample | Sample size (number) | Aztreonam % | Levofloxacin % | Ciprofloxacin % | Gentamicin % | Amikacin % | Tigecyclin % | Imipenem % | Meropenem % | Ertapenem | Cefatriaxone % |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
He et al. | 2017 | KP | 5 | 100 | 100 | 100 | 100 | ||||||
Jiang et al. | 2012 | KP | 1 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | |||
Jin et al. | 2015 | KP | 1 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | ||
Zheng et al. | 2016 | KP | 4 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | |||
Liu et al. | 2013 | KP | 1 | 100 | 100 | 100 | 100 | 100 | |||||
Zhang et al. | 2015 | KP | 3 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | ||
Zhang et al. | 2015 | KP | 1 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | |||
Qin et al. | 2014 | E.coli | 1 | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | ||
KP | 1 | 100 | 0 | 0 | 100 | 0 | 100 | 100 | 100 | ||||
Jin et al. | 2017 | KP | 1 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | |
Meidan | 100 | 0 | 50 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | |||
IQI 25% | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | |||
IQI 75% | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 |
First author | Publication year | Sample | Sample size (number) | Cefotaxime % | Ceftazidim % | Cefepime % | Cefoxitin % | Fosfomycin % | Piperacillin % | PIP/TZB % | Colsitin |
---|---|---|---|---|---|---|---|---|---|---|---|
He et al. | 2017 | KP | 5 | 100 | |||||||
Jiang et al. | 2012 | KP | 1 | 100 | 100 | 100 | 100 | 0 | |||
Jin et al. | 2015 | KP | 1 | 100 | 100 | 100 | 100 | 0 | 100 | 0 | |
Zheng et al. | 2016 | KP | 4 | 100 | 100 | 100 | 100 | ||||
Liu et al. | 2013 | KP | 1 | 100 | 100 | 100 | |||||
Zhang et al. | 2015 | KP | 3 | 100 | 100 | 100 | 100 | ||||
Zhang et al. | 2015 | KP | 1 | 100 | 100 | 100 | 100 | 100 | |||
Qin et al. | 2014 | E.coli | 1 | 100 | 100 | 0 | 100 | 0 | |||
KP | 1 | 100 | 100 | 0 | 100 | 0 | |||||
Jin et al. | 2017 | KP | 1 | 100 | 100 | 100 | 0 | 100 | 0 | ||
Meidan | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 0 | |||
IQI 25% | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 0 | |||
IQI 75% | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 0 |